RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis
Ponce Aix, S, Novello, S, Garon, EB, Nakagawa, K, Nadal, E, Moro-Sibilot, D, Alonso Garcia, M, Fabre, E, Frimodt-Moller, B, Zimmermann, AH, Visseren-Grul, CM, Reck, M
Published in Cancer treatment and research communications (2021)
Published in Cancer treatment and research communications (2021)
Get full text
Journal Article
1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
Nakagawa, K., Nadal, E., Garon, E.B., Nishio, M., Seto, T., Yamamoto, N., Park, K., Shih, J-Y., Frimodt-Moller, B., Zimmermann, A.H., Visseren-Grul, C.M., Reck, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)
Yoh, K., Atagi, S., Reck, M., Garon, E.B., Aix, S. Ponce, Moro-Sibilot, D., Winfree, K.B., Frimodt-Moller, B., Zimmermann, A.H., Visseren-Grul, C.M., Nakagawa, K.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
Aix, S., Novello, S., Garon, E., Nakagawa, K., Nadal, E., Moro-Sibilot, D., Garcia, M. Alonso, Fabre, E., Frimodt-Moller, B., Zimmermann, A., Visseren-Grul, C., Reck, M.
Published in Journal of thoracic oncology (01.10.2019)
Published in Journal of thoracic oncology (01.10.2019)
Get full text
Journal Article
35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
Gautschi, O., Drilon, A., Solomon, B., Tomasini, P., Loong, H.H.F., De Braud, F.G.M., Goto, K., Peterson, P., Barker, S., Liming, K., Frimodt-Moller, B., Park, K.
Published in ESMO open (01.03.2024)
Published in ESMO open (01.03.2024)
Get full text
Journal Article
Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
Besse, B., Barlesi, F., Ceccarelli, M., Chao, G.Y., Frimodt-Moller, B., Gil, M., Vansteenkiste, J.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
Besse, B., Barlesi, F., Demedts, I., Fuentes Pradera, J., Renault, A., Robinet, G., Frimodt-Moller, B., Gil, M., Vansteenkiste, J.
Published in Journal of thoracic oncology (01.04.2018)
Published in Journal of thoracic oncology (01.04.2018)
Get full text
Journal Article
Addressing the growing burden of trauma and injury in low- and middle-income countries
Fingerhut, Lois A, Harrison, James, Holder, Yvette, Frimodt-Møller, Birthe, Mackenzie, Susan, Mulder, Saakje, Scott, Ian
Published in American journal of public health (1971) (01.07.2005)
Published in American journal of public health (1971) (01.07.2005)
Get full text
Journal Article